===============================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
--------------------
FORM 10-K/A
(Mark One)
[X] Annual Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the fiscal year ended January 31, 1997
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the Transition Period from _______ to ______.
Commission file number 0-27568
PhyMatrix Corp.
(Exact name of registrant as specified in its charter)
----------------------
Delaware 65-0617076
(State of incorporation) (I.R.S. Employer Identification No.)
Phillips Point, Suite 1000E
777 S. Flagler Drive, West Palm Beach, Florida 33401
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (561) 655-3500
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $0.01 per share.
Indicate by check mark whether the registrant (1) has filed all reports
required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such Reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [_]
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definite proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [_]
On April 25, 1997, the aggregate market value of the voting stock held by
non-affiliates of the registrant was $137,682,609. On April 25, 1997, the
number of outstanding shares of the registrant's Common Stock, par value $0.01
per share, was 22,666,784.
================================================================================
<PAGE>
PART III
Item 10. Directors and Executive Officers of the Registrant
The following table sets forth certain information as of May 4, 1997
concerning the directors and executive officers of the Company.
<TABLE>
<CAPTION>
Name Age Position
- ---- --- --------
<S> <C> <C>
Abraham D. Gosman.......................... 67 Chairman of the Board of Directors and Chief Executive
Officer
Frederick R. Leathers...................... 39 Chief Financial Officer and Treasurer
Francis S. Tidikis......................... 49 Chief Operating Officer
William A. Sanger.......................... 47 Executive Vice President of Acquisitions
Edward E. Goldman, M.D..................... 52 Executive Vice President of Physician Development
Gregory Gardner............................ 41 Executive Vice President Finance
Don S. Harvey.............................. 39 Vice President of Operations
Alberto M. Hernandez....................... 36 General Counsel
Robert A. Miller........................... 42 Director and President
Eric Moskow................................ 38 Director and Executive Vice President Strategic Planning
Bruce A. Rendina........................... 43 Vice Chairman of the Board of Directors
Hugh L. Carey.............................. 78 Director
Joseph N. Cassese.......................... 67 Director
John T. Chay............................... 39 Director
David M. Livingston, M.D................... 56 Director
Stephen E. Ronai........................... 60 Director
</TABLE>
The following is a biographical summary of the experience of the executive
officers and directors of the Company:
Abraham D. Gosman has served since June 1994 as an executive officer of the
Company and is presently the Chairman of the Board of Directors and Chief
Executive Officer of the Company. Previously, he founded and was the principal
owner of The Mediplex Group, Inc. ("Mediplex"), a diversified health care
company, and its predecessor companies for more than 15 years, with the
exception of the period from April 1986 to August 1990 when Mediplex was owned
by Avon Products, Inc. ("Avon"). He was the Chief Executive Officer of Mediplex
from its inception to September 1988 and assumed that position again after
Mediplex was purchased from Avon in August 1990. In addition, Mr. Gosman has
served as Chairman of the Board of Trustees and Chief Executive Officer of
Meditrust, the nation's largest health care real estate investment trust, since
its inception in 1985. In October 1996, Mr. Gosman became Chairman of the Board
of Trustees of CareMatrix Corporation, an assisted living development and
management company.
-1-
<PAGE>
Frederick R. Leathers has served since June 1994 as the Chief Financial
Officer and Treasurer of the Company. Previously, he served as Treasurer, Chief
Financial Officer and Principal Accounting Officer of Mediplex from October 1991
to June 1994, Corporate Controller from May 1991 to October 1991 and held the
position of Assistant Controller from May 1986 to May 1987. He was Treasurer of
A.M.A. Advisory Corp. (the advisor to Meditrust) and Controller of Meditrust
from July 1988 to January 1991. Mr. Leathers was associated with State Street
Bank and Trust Company, Inc. in the mutual funds division from May 1987 to July
1988.
Francis S. Tidikis has been the Company's Chief Operating Officer since
November 1996. He also served from January 1996 to March 1996 as the Company's
Executive Vice President of Marketing and from March 1996 to October 1996 as its
Executive Vice President of Operations. Previously, Mr. Tidikis was Senior Vice
President of Physician Management Services for Tenet Healthcare Corporation from
March 1995 to January 1996. Mr. Tidikis had been with Tenet Healthcare
Corporation and its predecessor, National Medical Enterprises, since April 1981,
serving as Executive Vice President of the Eastern District from June 1991 to
February 1995 and as Vice President of Operations for the Eastern Region
Hospital Group from February 1984 to September 1990. Mr. Tidikis currently
serves as a director of Professional Liability Insurance Company.
William A. Sanger has served since September 1994 as an Executive Vice
President of the Company. Previously, he served as the President and Chief
Executive Officer of JFK Medical Center in Atlantis, Florida from February 1992
to September 1994 where he developed integrated delivery networks and
implemented a comprehensive physician acquisition strategy. He served as
Executive Vice President and Chief Operating Officer of Saint Vincent Medical
Center, Toledo, Ohio from January 1990 to February 1992.
Edward E. Goldman, M.D. has served since October 1994 as President of a
subsidiary of the Company, since October 1995 as an executive officer of the
Company and is presently Executive Vice President of Physician Development. Dr.
Goldman is a board certified family practice physician and previously served as
Chairman of PAL-MED Health Services from February 1983 to September 1994, a
multi-specialty IPA which provides physicians services and manages health care
related services.
Gregory Gardner has served since November 1996 as Executive Vice President
Finance of the Company. Previously, he served as Senior Vice President,
Financial Operations of Good Samaritan & St. Mary's Medical Centers from August
1995 to November 1996. From November 1990 to December 1993 Mr. Gardner served as
American Medical International, Inc.'s Corporate Director of Finance and from
January 1994 to July 1995 as its Corporate Director of Development.
Don S. Harvey has served as an operations officer of the Company since
April 1995 and as an executive officer since October 1995 and is presently
Senior Vice President of Operations. He was a consultant to the Company from
January 1995 to April 1995. Mr. Harvey served as Executive Vice President and
Chief Operating Officer of JFK Medical Center in Atlantis, Florida from April
1990 to December 1994, where he developed and managed medical related services.
Alberto M. Hernandez has served as general counsel since July 1996 and as
an executive officer since March 1997. Mr. Hernandez was associated with the
Miami, Florida law firm of Greenberg, Traurig, Hoffman, Lipoff, Rosen & Quentel,
P.A. from March 1991 through June 1996.
Robert A. Miller has been the Company's President and a director of the
Company since March 1997. He also served from June 1994 to February 1997 as the
Company's Executive Vice President of Acquisitions. Previously, he served as
Senior Vice President/Development Operations of Mediplex from September 1992 and
Vice President from June 1991. Mr. Miller served as Regional Operations Director
for New Medico Associates from January 1991 to October 1991. Previously, Mr.
Miller was Vice President of Hospital Operations of Glenbeigh, Inc., where he
was employed from 1979 through 1991.
Eric Moskow, M.D, has served as a director of the Company and has been
Executive Vice President of Strategic Planning of the Company since September
1996. He founded Physician's Choice Management, LLC ("Physician's Choice") in
October 1995 and served as its Executive Vice President from October 1995 to
October 1996. Prior to establishing Physician's Choice, he served as Medical
Director for Mediplex of Ridgefield from
-2-
<PAGE>
November 1994 to August 1996 and as Associate Medical Director for US Healthcare
in Connecticut from 1988 to 1990. Dr. Moskow is board-certified in internal
medicine and has served as President of the Family Medical Associates of
Ridgefield for the past nine years,
Bruce A. Rendina has served as a director of the Company since January 29,
1996 and assumed the role of Vice Chairman of the Board of Directors in March
1997. Mr. Rendina has served since 1994 as President of DASCO, which he
co-founded. Previously, he served as its Executive Vice President from 1987 to
1994.
Hugh L. Carey has served as a director of the Company since February 21,
1996. Currently, he is Chairman of the Board of Advisors of Cambridge Partners,
L.L.C. He served as an Executive Vice President of W.R. Grace & Company from
January 1989 to December 1995. He was Governor of the State of New York from
January 1974 to January 1982. He is currently a director of Triarc Companies,
Inc.
Joseph N. Cassese has served as a director of the Company since January 29,
1996. Mr. Cassese was the Vice President of Mediplex from January 1976 to March
1986 and the President of Mediplex from March 1986 to March 1988 and again from
August 1990 to December 1991. Mr. Cassese was also a Vice President of A.M.A.
Advisory Corp., the advisor to Meditrust, from April 1988 to August 1990. Mr.
Cassese has been retired since December 1991.
John T. Chay has served as a director of the Company since April 15, 1996.
Mr. Chay has served as an executive officer of Nutrichem, Inc. which he
co-founded in November 1993 and has served since June 1991 as Chief Executive
Officer of The HealthLink Group, Inc., a practice management consulting firm
which he also founded.
David M. Livingston, M.D. has served as a director of the Company since
January 29, 1996. Dr. Livingston has been a Director of Dana-Farber Cancer
Institute in Boston, Massachusetts since 1991 and has been employed as a
physician at the Institute since 1973. He currently serves as Chairman of the
Institute's Department of Medicine and Executive Committee for Research and as a
Trustee of the Institute. He is also the Emil Frei Professor of Medicine at
Harvard Medical School where he has taught since 1973.
Stephen E. Ronai has served as a director of the Company since January 29,
1996. Mr. Ronai has been a partner in the Connecticut law firm of Murtha,
Cullina, Richter and Pinney since 1984 where he serves as Chairman of the firm's
Health Care Department. He is a member of the American Academy of Healthcare
Attorneys of the American Hospital Association and the National Health Lawyers
Association. From 1989 to 1995 he served as a member of the Board of Directors
of the National Health Lawyers Association. He also formerly served as Chairman
of the Board of Trustees of the Connecticut Hospital Association.
Section 16(a) Beneficial Ownership Reporting Compliance
Messrs. Gosman, Leathers, Sanger, Miller, Goldman, Tidikis, Harvey, Sands,
Cassesse, Rendina and Ronai and Dr. Goldman each filed their Form 3 with the
Securities and Exchange Commission (the "SEC") on March 19, 1996. The Company's
common stock was registered under the Securities Act on January 23, 1996. Mr.
Carey filed his Form 3 with the SEC on April 20, 1996. Mr. Carey became a
director of the Company on February 21, 1996. Mr. Gardner filed his Form 3 with
the SEC on May 29, 1997. Mr. Gardner became an executive officer of the Company
on November 17, 1996. Mr. Gosman filed a Form 4 with the SEC on October 8, 1996
with respect to two transactions and an amended Form 4 with the SEC on January
6, 1997 with respect to four transactions. Mr. Harvey filed a Form 4 with the
SEC on March 31, 1996 with respect to three transactions.
Item 11. Executive Compensation
The following table sets forth certain information regarding compensation
paid or accrued by the Company during the period June 24, 1994 (inception) to
December 31, 1994, the year ended December 31, 1995 and the fiscal year ended
January 31, 1997, to the Company's Chief Executive Officer and to five other
executive officers of the Company (the "Named Executive Officers").
-3-
<PAGE>
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
Long-Term
Compensation Awards
Annual -------------------- All Other
Compensation Securities Underlying Compensation (2)
Name and Principal Position Year(1) Salary ($) Options (#) ($)
--------------------------- ------- ------------ ------------- -----------------
<S> <C> <C> <C> <C>
Abraham D. Gosman................................ 1997 225,000 -- --
Chairman and Chief Executive Officer 1995 225,000 -- --
1994 116,682 --
Donald A Sands (3)(4)............................ 1997 462,026 -- 87,015
Vice President - Medical Facility Development
Bruce A. Rendina (3)............................. 1997 435,782 -- 53,948
President of DASCO Development Corporation
Edward E. Goldman, M.D........................... 1997 398,473 -- --
Executive Vice President of Physician Development 1995 400,000 -- --
1994 133,333 --
William A. Sanger................................ 1997 304,976 -- --
Executive Vice President 1995 304,571 -- 174
1994 98,038 --
Francis S. Tidikis (3)........................... 1997 275,156 150,000(5) --
Chief Operating Officer
</TABLE>
(1) In January 1996, the Company changed its fiscal year end from December 31
to January 31.
(2) Amounts indicated are for life insurance premiums paid by the Company.
(3) Messrs. Sands, Rendina and Tidikis became executive officers of the Company
in January 1996.
(4) Mr. Sands' employment with the Company terminated in January 1997.
(5) Represents options granted to Mr. Tidikis on January 23, 1996.
Option Grants in Last Fiscal Year
The following table sets forth certain information regarding options
granted during the fiscal year ended January 31, 1997 by the Company to each of
the Named Executive Officers:
-4-
<PAGE>
<TABLE>
<CAPTION>
Potential Realizable
Value at Assumed
Rates of
Stock Price
Appreciation
for Option
Individuals Grants Term (A)
- ------------------------------------------------------------------------------------------ ---------------------------------
% of Total
Number of Options
Securities Granted to Exercise
Underlying Employees or
Options in Fiscal Base Expiration
Name Granted (#) Year Price ($/Sh) Date 5% ($) 10% ($)
- ---------------------------------------- ------ ------------ ------ -------- --------
<S> <C> <C> <C> <C> <C> <C>
Abraham D. Gosman........ -- --% $ -- -- $ -- $ --
Donald A. Sands.......... -- -- -- -- -- --
Bruce A. Rendina......... -- -- -- -- -- --
Edward E. Goldman........ -- -- -- -- -- --
William A. Sanger........ -- -- -- -- -- --
Francis S. Tidikis....... 100,000 6.1 $15.00 1/23/06 1,636,000 3,493,000
10,000 * $18.375 1/23/06 129,850 315,550
40,000 2.5 (B) 1/23/06 674,400(C) 1,417,200(C)
</TABLE>
- ---------------------------
*Less than 1%
(A) Amounts represent hypothetical gains that could be achieved for the
respective options if exercised at the end of the option term. These gains
are based on assumed rates of stock appreciation of 5% and 10% compounded
annually from the date the respective options were granted to their
expiration date. Actual gains, if any, on stock option exercises will
depend on the future performance of the Common Stock and the date on which
the options are exercised. The Company has not granted stock appreciation
rights to date.
(B) Fair market value on the date such options become exercisable.
(C) Assuming an exercise price of $14.50 (the closing price of the Common Stock
on The Nasdaq National Market on May 9, 1997).
Aggregated Option Exercises in Last Fiscal Year and
Fiscal Year-End Option Values.
The Named Executive Officers did not exercise any options during the fiscal
year ended January 31, 1997. As of such date, Mr. Tidikis held options to
purchase 150,000 shares of the Common Stock, 30,000 shares of which were
exercisable. None of the other Named Executive Officers held options as of such
date. The value of the exercisable portion of Mr. Tidikis' options was $17,500
and the value of the unexercisable portion of his options was $70,000. Value is
calculated on the basis of the difference between the option exercise price and
$15.875, the closing price for the Common Stock on The Nasdaq National Market on
January 31, 1997, multiplied by the number of shares of the Common Stock
underlying the option. No value is determinable with respect Mr. Tidikis' option
to purchase 40,000 shares of the Common Stock which is unexercisable and which
will have its exercise price determined on the date that it becomes exercisable.
-5-
<PAGE>
Compensation of Directors
Officers who are members of the Board of Directors do not receive
compensation for serving on the Board. Each other member of the Board receives
annual compensation of $15,000 for serving on the Board, plus a fee of $1,000
for each Board of Directors' meeting attended. In addition, such directors
receive an additional fee of $500 for each committee meeting attended, except
that only one fee will be paid in the event that more than one such meeting is
held on a single day. All directors receive reimbursement of reasonable expenses
incurred in attending Board and committee meetings and otherwise carrying out
their duties. Each non-employee director who was a member of the Compensation
Committee at the time of the closing of the Initial Public Offering received
options to purchase 10,000 shares of Common Stock at the offering price pursuant
to the Equity Plan. Each director who is a member of the Compensation Committee
on the first business day following each annual meeting of the shareholders will
receive the option to purchase 2,500 shares of Common Stock. Any of such options
granted to a member of the Compensation Committee under the Equity Plan will be
exercisable one year following the date of grant.
Employment Agreements
The Company has entered into an employment agreement with Mr. Rendina that
provides for an initial one year term automatically renewable for successive one
year periods until either party elects not to renew. The base salary for Mr.
Rendina under the agreement is $330,000 per year. In addition, he is entitled to
receive bonuses and benefits, including life, accident, health and dental
insurance. The agreement may be terminated by the Company without cause upon 90
days notice and with cause effective immediately upon notice. The agreement may
be terminated by Mr. Rendina immediately upon notice.
The Company has entered into an employment agreement with Dr. Goldman that
provides for an initial three year term automatically renewable for an initial
period of two years and for successive periods of one year thereafter, unless
either party elects not to renew. The base salary for Dr. Goldman under the
agreement is $400,000 per year. In addition, he is entitled to receive bonuses
and benefits, including health insurance, dental insurance, short and long term
disability, life insurance and a car allowance. The agreement may be terminated
by the Company without cause upon 30 days notice (180 days notice after the
first anniversary of the agreement) and with cause (as defined in the agreement)
effective immediately upon notice. Dr. Goldman may terminate the agreement
immediately if the Company fails to fulfill its obligations thereunder or
without cause upon 30 days notice. In the event that Dr. Goldman is terminated
without cause, he is entitled to receive his base salary for the lesser of (i)
the remaining term of the then current employment period or (ii) 12 months
following the effective date of his termination of employment. The agreement
contains restrictive covenants prohibiting Dr. Goldman from competing with the
Company, or soliciting employees of the Company to leave, during his employment
and for a period of two years after termination of the agreement other than
after a termination by the Company without cause or by Dr. Goldman for good
reason.
The Company has entered into an employment agreement with Mr. Sanger that
provides for an initial three year term that is automatically renewable for
successive one year periods until either party elects not to renew. The base
salary for Mr. Sanger under the agreement is $300,000 per year. In addition, he
is entitled to receive bonuses and benefits, including health insurance, dental
insurance, short and long term disability, life insurance and a car allowance.
The agreement may be terminated by the Company without cause and with cause (as
defined in the agreement) effective immediately upon written notice. Mr. Sanger
may terminate the agreement upon written notice to the Company, if the Company
fails to pay any sums due or perform substantially all of its duties and
obligations under the agreement. In the event that Mr. Sanger is terminated
without cause, he is entitled to receive his base salary for 12 months following
the effective date of his termination of employment. The agreement contains
restrictive covenants prohibiting Mr. Sanger from competing with the Company, or
soliciting employees of the Company to leave during his term of the agreement
and for a period of twelve months thereafter (if Mr. Sanger is terminated with
cause or if he chooses not to renew the agreement).
-6-
<PAGE>
Item 12. Security Ownership of Certain Beneficial Owners and Management
The following table sets forth, as of April 25, 1997, certain information
regarding the beneficial ownership of shares of Common Stock by each person
known by the Company to be the beneficial owner of more than 5% of outstanding
Common Stock, by each director and each of the Named Executive Officers of the
Company and by all directors and executive officers as a group. Except as
indicated in the footnotes, all of such shares of Common Stock set forth in the
following table are owned directly, and the indicated person has sole voting and
investment power with respect to all Common Stock shown as beneficially owned by
such person:
Amount of Beneficial Ownership
Shares
Beneficially Percentage
Name Owned Owned
- ---- ----------- -------
Abraham D. Gosman (1)......................... 8,487,126 37.4%
Putnam Investments, Inc. (2).................. 2,322,300 10.2
Donald A. Sands (3)........................... 908,334 4.0
Bruce A. Rendina (4).......................... 908,333 4.0
Edward E. Goldman, M.D........................ 168,112 *
William A. Sanger............................. 336,224 1.5
Francis S. Tidikis (5)........................ 31,085 *
Hugh L. Carey................................. -- *
Joseph N. Cassese (6)......................... 30,000 *
John T. Chay.................................. 142,833 *
David M. Livingston, M.D...................... -- *
Eric Moskow (7)............................... 175,252 *
Stephen E. Ronai (8).......................... 14,000 *
All directors and executive officers
as a group (16 persons) (9).................. 12,190,791 53.8
* Less than one percent.
(1) Includes 4,000,000 shares held by Mr. Gosman as trustee for the benefit of
his two adult sons. Mr. Gosman's business address is PhyMatrix Corp., 777
South Flagler Drive, West Palm Beach, FL 33401.
(2) Putnam Investments, Inc. ("PIT") and its wholly-owned subsidiary Putnam
Investment Management, Inc. ("PIM") have shared dispositive power with
respect to such shares, including 1,096,700 shares with respect to which
Putnam New Opportunities Fund (the "Fund") has shared voting and
dispositive power. The address of PIT, PIM and the Fund is One Post Office
Square, Boston, Massachusetts 02109. The foregoing is based upon the
Schedule 13G dated July 10, 1996 filed by PIT, PIM and the Fund.
(3) Represents shares held by two limited partnerships controlled by Mr.
Rendina.
(4) Represents shares held by two limited partnerships controlled by Mr. Sands
and his wife.
-7-
<PAGE>
(5) Includes 85 shares owned by Mr. Tidikis' wife with respect to which Mr.
Tidikis disclaims beneficial ownership and 30,000 shares which Mr. Tidikis
has the right to acquire beneficial ownership of upon exercise of an
option.
(6) Includes 10,000 shares which Mr. Cassese has the right to acquire
beneficial ownership of upon exercise of an option.
(7) Includes 100,000 shares which Dr. Moskow has the right to acquire
beneficial ownership of upon exercise of an option.
(8) Includes 10,000 shares which Mr. Ronai has the right to acquire beneficial
ownership of upon exercise of an option.
(9) Includes 218,332 shares which the directors and executive officers have the
right to acquire beneficial ownership of upon exercise of an option.
Item 13. Certain Relationships and Related Transactions
During 1994 and 1995, the Related Companies and Mr. Gosman completed the
acquisition of various companies and businesses which were transferred to the
Company in connection with the Formation.
As of January 31, 1997, the Company had no outstanding borrowings from Mr.
Gosman. At December 31, 1995 the Company had a $19.5 million loan from
NationsBank, which was guaranteed by Mr. Gosman. Mr. Gosman did not receive any
consideration for this or any other guarantee he has provided on behalf of the
Company. The $19.5 million loan was repaid from the net proceeds of the initial
public offering. After repayments to Mr. Gosman made from the net proceeds of
the initial public offering totalling $28.7 million, the Company owed Mr. Gosman
approximately $10.8 million, which was repaid from the net proceeds of the Debt
Offering. All amounts loaned to the Company by Mr. Gosman accrue interest at a
floating rate equal to NationsBank's prime rate. The Company agreed to repay in
full the amount owed to Mr. Gosman from the proceeds of any public offering by
the Company of its debt or equity securities and to repay Mr. Gosman from the
proceeds of any institutional debt financing by the Company for working capital
purposes, except that the amount to be repaid from such institutional debt
financing proceeds would not exceed 25% of the maximum amount available to be
borrowed under the terms of the financing. Pursuant to such agreement, the $11.7
million the Company owed Mr. Gosman (including additional amounts borrowed since
the closing of the initial public offering) was repaid from the net proceeds of
the Debt Offering.
In connection with the acquisition of OTI in March 1995, Mr. Gosman
guaranteed until the later of the satisfaction of certain financial covenants or
July 31, 1998 the repayment by a subsidiary of the Company of a portion of the
$17.5 million in acquisition financing from FINOVA Capital Corporation
("FINOVA"). Mr. Gosman's liability under the guarantee was limited to no more
than $6.1 million. The Company used the net proceeds of the initial public
offering to repay in full its obligations to FINOVA.
During 1995, in addition to the guarantee discussed above, Mr. Gosman
guaranteed the payment by the Company of indebtedness in the amount of $4.6
million incurred in connection with the acquisition of DASCO, all of which was
repaid during 1996. In addition, Mr. Gosman executed a reimbursement agreement
and provided collateral for a letter of credit to secure other indebtedness of
the Company in the amount of $5.4 million incurred in connection with the
acquisition of Oncology & Radiation Associates, P.A. Upon the closing of the
initial public offering, the Company obtained the release of Mr. Gosman from
these guarantees and from his other obligations
-8-
<PAGE>
with respect to acquisition indebtedness through the assumption by the Company
of Mr. Gosman's obligation to pay such Acquisition indebtedness and of the
obligation to provide cash collateral for the letter of credit.
The Company occupies office space for its principal offices in West Palm
Beach, Florida under the terms of a lease which the Company assumed from a
company the stockholders and executive officers of which include Messrs. Gosman,
Leathers, Miller and Sanger and Dr. Goldman. The Company estimates that the
total amount of lease payments to be made under the assumed lease through the
end of the current lease term will equal approximately $900,000.
In connection with the Formation, the following executive officers and
directors of the Company received the indicated number of shares of Common Stock
in exchange for their shares of common stock of the Related Companies: Mr.
Gosman (including shares held for the benefit of his two adult sons), 8,282,305;
Mr. Rendina, 916,667; Mr. Chay, 133,333; Mr. Sands, 916,667; Mr. Leathers,
459,505; Mr. Miller, 459,505; Mr. Sanger, 336,224; and Dr. Goldman, 168,112.
Various persons who upon the closing of the initial public offering and the
Formation became employees and/or officers of the Company were employees and/or
officers of companies the stockholders and executive officers of which included
Mr. Gosman and Mr. Leathers. The services of such employees and/or officers were
provided to the Company at cost prior to the Formation under the terms of a
management agreement.
DASCO provides development and other services in connection with the
establishment of health parks, medical malls and medical office buildings. DASCO
provides these services to or for the benefit of the owners of the new
facilities, which owners are either corporations or limited partnerships. Mr.
Sands and Mr. Rendina have obtained equity interests in the entities which own
26 of the 29 facilities developed by DASCO. The collective interests of Messrs.
Sands and Rendina range from 17% to 100%. In addition, Mr. Gosman individually
and as trustee for his two sons and Frederick R. Leathers, Robert A. Miller,
William A. Sanger and Edward E. Goldman have obtained limited partnership
interests ranging from 14% to 36% in the entities which own 11 facilities being
developed by the Company through DASCO. During the year ended January 31, 1991,
DASCO recorded revenues in the amount of approximately $10 million related to
facilities developed by DASCO in which equity interests have been obtained by
related parties.
The Company provides construction management, development marketing and
consulting services to entities principally owned by Mr. Gosman in connection
with the development and operation by such entities of several medical
facilities. During the year ended January 31, 1997, the Company recorded
revenues in the amount of approximately $7 million related to such services. The
Company provides these services to affiliated parties on terms no less favorable
to the Company than those provided to unaffiliated parties.
Meditrust, a publicly traded real estate investment trust with assets in
excess of $2.4 billion dollars of which Mr. Gosman is the Chairman of the Board
and Chief Executive Officer, has provided financing in the aggregate amount of
$176.0 million for the development of 19 facilities developed by DASCO.
Mr. Ronai is a partner in the Connecticut law firm of Murtha, Cullina,
Richter and Pinney which has been retained to perform certain legal services for
the Company.
During December 1995, the Company obtained a 43.75% interest in Physicians
Choice Management, LLC, a newly formed management services organization that
provides management services to an independent physician association composed of
over 300 physicians based in Connecticut ("Physician's Choice"). The Company
acquired this interest in exchange for a payment of $1.5 million to the
stockholders of Physician's Choice, including Dr. Moskow. During September 1996,
the Company acquired the remaining 56.25% interest from such stockholders for a
payment of $1 million in cash plus 363,442 shares of the Company's Common Stock.
-9-
<PAGE>
The Company loaned the shareholders of Physician's Choice, including Dr.
Moskow, an aggregate of $2.3 million to pay the tax liability related to the
sale of Physician's Choice. The loans are secured by a pledge of the Common
Stock held by the former shareholders of Physician's Choice.
The Company leases space on behalf of its affiliated physicians at
competitive rates at Palm Beach Gardens medical mall. Mr. Gosman owns a limited
partnership interest in the limited partnership which is general partner of the
limited partnership which owns the medical mall. The aggregate base rent under
such leases is approximately $657,000.
During November 1994, the Company acquired Nutrichem. In connection with
the acquisition, the Company was required to make contingent note payments of
$4.4 million to the stockholders of Nutrichem, including Mr. Chay. The Company
paid in full the contingent note with the proceeds of the initial public
offering.
In connection with an acquisition, the Company was required to assume an
unfavorable lease which was assigned in January 1997 to an entity principally
owned by Mr. Gosman. The difference between the cost and value of the lease is
approximately $559,000.
-10-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this amendment to its Annual Report on
Form 10-K to be signed on its behalf by the undersigned, thereunto duly
authorized on the 30th day of May, 1997.
PHYMATRIX CORP.
By: /s/ Frederick R. Leathers
---------------------------------------
Chief Financial Officer, Treasurer
and Principal Accounting Officer
-11-
